• Have any questions?
  • +1-888-INTL-SOS
  • support@globalreachhealth.com
  • Home
  • About
    • About
    • Licensure and Compliance
    • Company Brochure
    • Leadership
    • Careers
  • Divisions
    • Global Reach Rx
      • Service Countries
      • Pharmacy Discount Card
    • Global Reach Rx USA
    • Global Reach Arabia
    • Global Reach Pharma
    • Global Reach Financial Services
    • Global Reach Technology Services
    • Global Reach Miracle Foundation
    • Global Reach Health Clinic
    • Now Salud
  • Member Savings Programs
    • Wellevate Store
    • Pharmacy Discount Card
    • American Vaccine
    • Global immunization
  • News
  • Contact
  • Accessibility
  • Cookie Policy
  • Contact Us
  • Legal Disclaimer
  • Privacy Policy
  • Security
  • Sitemap
✕

Xpovio Granted New Multiple Myeloma Indication

  • Home
  • News
  • Global Reach Health News
  • Xpovio Granted New Multiple Myeloma Indication
Third Biosimilar for Rituxan Approved
December 17, 2020
Tagrisso Receives New Indication for Lung Cancer
December 18, 2020
Third Biosimilar for Rituxan Approved
December 17, 2020
Tagrisso Receives New Indication for Lung Cancer
December 18, 2020

Related posts

OTHER ANNOUNCEMENTS AND ARTICLES


Read more

GENERIC DRUG APPROVALS


Read more

FDA Approves Otulfi™, a Biosimilar to Stelara®


Read more

About Global Reach Health

Global Reach Health is a diverse group of global healthcare divisions and partners delivering healthcare solutions across the globe.

Global Reach Health administrates five separate divisions to deliver seamless cross border healthcare solutions and services for a myriad of clients around the globe including insurers, pharmacies, hospitals and clinics, assistance firms, cost containment companies, third party administrators plus public entities and private corporations.

Important Links

  • Accessibility
  • Cookie Policy
  • Contact Us
  • Legal Disclaimer
  • Privacy Policy
  • Security
  • Sitemap
© 2019 - 2026 Global Reach Health. All Rights Reserved.
Contact